Colby Pharmaceutical Company to treat metastatic prostate cancer after the prostate is removed

One of the most unhappy groups of men is a group with a prostate cancer biomarker(PSA) in peripheral blood after their prostate has been removed. If the disease is metastasized in the bone, the prognosis for these men is very poor.

However, Colby Pharmaceutical Company (www.colbypharma.com), is working on bringing highly potent oxidative stress modulating drugs to market that show efficacy in pre-clinical trials.

What is PSA:
Prostate specific antigen (PSA) is a protein produced by the cells of the prostate gland. PSA is present in small quantities in the serum of normal men, and is often elevated in the presence of prostate cancer and in other prostate disorders. A blood test to measure PSA is the most effective test currently available for the early detection of prostate cancer. Rising levels of PSA over time are associated with both localized and metastatic prostate cancer (CaP).